Sign In
Buy ITCI
$131.87
+0 (+0%)
At Close: Jul 01, 2025
Saifullah Mir aka Ghazi Haider, 26, is Hizbul’s new face of terror in Kashmir
05:43pm, Sunday, 10'th May 2020
Saifullah Mir was inducted into terrorism by Riyaz Naikoo in 2014 and had moved up the Hizbul Mujahideen hierarchy along with his mentor
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
01:52pm, Saturday, 09'th May 2020
The investors in Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) will be rubbing their hands together with glee today...
US Might Work With Huawei On 5G Network After All - Techzim
11:13am, Saturday, 09'th May 2020
Whilst US-China relations are still not patched up it seems the USA is softening its stance on a Huawei-enabled 5G rollout. After repeatedly urging other countries such as the UK, and France not to us
Intra-Cellular Therapies Inc (ITCI) Q1 2020 Earnings Call Transcript
09:00pm, Friday, 08'th May 2020
Joining me on the call today are Dr. Sharon Mates, Chairman and Chief Executive Officer; Dr. Andrew Satlin, Executive Vice President and Chief Medical Officer; Mark Neumann, Executive Vice President a
Intra-Cellular Therapies (ITCI) Reports Q1 Loss, Misses Revenue Estimates
03:05pm, Thursday, 07'th May 2020
Intra-Cellular (ITCI) delivered earnings and revenue surprises of 25.51% and -38.11%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
US Considering 5G Collab With China's Huawei | PYMNTS.com
02:59pm, Thursday, 07'th May 2020
The U.S. Department of Commerce (DoC) is on the verge of green-lighting collaboration with Huawei Technologies in China to cooperatively develop 5G standards.
Intra-Cellular Therapies Q1 EPS $(0.730) Beats $(0.930) Estimate, Sales $1.083M Miss $1.440M Estimate
12:12pm, Thursday, 07'th May 2020Intra-Cellular Therapies Reports First Quarter 2020 Financial Results and Provides Corporate Update
11:30am, Thursday, 07'th May 2020
NEW YORK, May 07, 2020 -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for.
